New Zealand Data Sheet

1. PRODUCT NAME

PENTHROX® 1.5 mL volatile liquid for inhalation
PENTHROX® 3 mL volatile liquid for inhalation

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

PENTHROX 1.5 mL bottle contains 1.5 mL of Methoxyflurane 99.9% w/w.
PENTHROX 3 mL bottle contains 3 mL of Methoxyflurane 99.9% w/w.

Excipient(s) with known effect

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Volatile liquid for inhalation.
Clear, almost colourless mobile liquid, with a characteristic odour (mildly pungent odour).

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

- For emergency relief of pain by self-administration in conscious haemodynamically stable patients with trauma and associated pain, under supervision of personnel trained in its use (see section 4.2).
- For the relief of pain in monitored conscious patients who require analgesia for surgical procedures such as the change of dressings (see section 4.2).

4.2. Dose and method of administration

FOR USE ONLY AS AN ANALGESIC AGENT, SEE SECTION 4.3 CONTRAINDICATIONS

PENTHROX (methoxyflurane) is self-administered under supervision (and assisted if necessary) by a person trained in its administration using the handheld PENTHROX® Inhaler. The cumulative dose received by patients receiving intermittent doses of PENTHROX® (methoxyflurane) for painful procedures (such as wound dressings) must be carefully monitored to ensure that the recommended dose of methoxyflurane is not exceeded.

Dose

Adults
One bottle of PENTHROX (1.5 mL or 3 mL) to be vaporised in a PENTHROX inhaler. On finishing the initial bottle, another bottle may be used. The refilling must be conducted in a well-ventilated area to reduce environmental exposure to Methoxyflurane vapour. Up to 6 mL may be administered per day; the total maximum dose must not be exceeded.

Patients should be instructed to inhale intermittently to achieve adequate analgesia. Continuous administration will reduce time of analgesia. To maximise safety, the lowest effective dosage of PENTHROX (methoxyflurane) to provide analgesia should be used particularly for children and the elderly. Administration on consecutive days or daily use is not recommended because of nephrotoxic potential. The cumulative dose received by patients receiving intermittent doses of PENTHROX (methoxyflurane) for painful procedures (such as wound dressings) must be carefully monitored to ensure that the recommended dose of methoxyflurane is not exceeded and the total weekly dose should not exceed 15 mL. Exceeding the recommended dose may cause renal failure (see section 4.4), Methoxyflurane-associated renal failure is generally irreversible.

**Special populations**

**Children**

Limited data is available regarding the administration of PENTHROX using the PENTHROX Inhaler (see section 4.4). The minimum effective dose to produce analgesia should be administered to children.

**Elderly population**

The minimum effective dose to produce analgesia should be administered (see section 4.4).

**Method of Administration**

PENTHROX (methoxyflurane) is self-administered under supervision (and assisted if necessary) by a person trained in its administration using the handheld PENTHROX Inhaler.

Instructions on the preparation of the PENTHROX Inhaler and correct administration are provided below.

1. Ensure the Activated Carbon (AC) Chamber (where applicable) is inserted into the dilutor hole on the top of the Penthrox Inhaler.

2. Holding the Penthrox bottle upright, use the base of the Penthrox Inhaler to loosen the cap with a 1/2 turn. Separate the Inhaler from the bottle and remove the cap by hand.
3 Tilt the Penthrox Inhaler to a 45° angle and pour the contents of one bottle into the base whilst rotating.

4 Place wrist loop over patient’s wrist. Patient inhales through the mouthpiece of Inhaler to obtain analgesia. First few breaths should be gentle and then breathe normally through Inhaler.

5 Patient exhales into Inhaler. The exhaled vapour passes through the AC Chamber to adsorb any exhaled methoxyflurane.

6 If stronger analgesia is required, patient can cover dilutor hole with finger during inhalation.

7 Patient should be instructed to inhale intermittently to achieve adequate analgesia. Continuous administration will reduce time of analgesia. Patients should be administered the minimum dose they require.

8 Replace cap onto Penthrox bottle. Place used Penthrox Inhaler and used bottle in a sealed plastic bag and dispose of responsibly (see Section 6.6 Special Precautions for Disposal).

4.3. Contraindications

- Use as an anaesthetic agent
- Renal impairment, including reduced glomerular filtration rate (GFR), urine output and reduced renal blood flow.
- Renal failure
- Hypersensitivity to methoxyflurane, any fluorinated anaesthetics or to any ingredients in PENTHROX
- Cardiovascular instability
- Respiratory depression
- Head injury or loss of consciousness
- A history of possible adverse reactions in either patient or relatives
- Malignant hyperthermia: patients with known or genetically susceptible to malignant hyperthermia

4.4. Special warnings and precautions for use

Renal disease

Methoxyflurane impairs renal function in a dose-related manner due to the effect of the released fluoride on the distal tubule and may cause polyuric or oliguric renal failure, oxaluria being the prominent feature. Nephrotoxicity is greater with methoxyflurane than with other halogenated anaesthetics because of the slower metabolism over several days resulting in prolonged production of fluoride ions and metabolism to other potentially nephrotoxic substances. Methoxyflurane-associated renal failure is generally irreversible. **Because of the potential nephrotoxic effects methoxyflurane must not be used as an anaesthetic agent.** The risk is related to the total dose (time and concentration) and frequent exposure. Furthermore, the lowest effective dose of PENTHROX should be administered, especially in elderly or obese patients (see section 5.2).

Daily use of methoxyflurane is not recommended because of nephrotoxic potential.

Liver disease

It is not advisable to administer PENTHROX to patients who have shown signs of liver damage, especially after previous methoxyflurane or halothane anaesthesia. There have also been occasional reports of hepatic dysfunction, jaundice, and fatal hepatic necrosis associated with methoxyflurane use (see section 4.8).

Paediatric Use

Limited data is available regarding the administration of methoxyflurane using the PENTHROX Inhaler. The minimum effective dose to produce analgesia should be administered to children.

Paediatric neurotoxicity

Some published studies in children have observed cognitive deficits after repeated or prolonged exposures to anaesthetic agents early in life. These studies have substantial limitations, and it is not clear if the observed effects are due to the anaesthetic/analgesic/sedation medicine administration or other factors such as the surgery or underlying illness.

Published animal studies of some anaesthetic/analgesic/sedation medicines have reported adverse effects on brain development in early life and late pregnancy. The clinical significance of these nonclinical findings is yet to be determined.

With inhalation or infusion of such medicines, exposure is longer than the period of inhalation or
infusion. Depending on the medicine and patient characteristics, as well as dosage, the elimination phase may be prolonged relative to the period of administration.

**Diabetic patients**

Diabetic patients may have an increased likelihood of developing nephropathy if they have impaired renal function or polyuria, are obese, or are not optimally controlled.

**Use in elderly**

Caution should be exercised in the elderly due to possible reduction in blood pressure or heart rate.

**Respiratory depression**

Respiratory depression has been reported also from analgesic doses of methoxyflurane. Respiration should be monitored due to the risk of respiratory depression and hypoxia.

**Occupational exposure**

Healthcare professionals who are regularly exposed to patients using PENTHROX® inhalers should be aware of any relevant occupational health and safety guidelines for the use of inhalational agents. To reduce occupational exposure to methoxyflurane, the PENTHROX® Inhaler should be used with the Activated Carbon (AC) Chamber. Patients should be instructed to exhale into the PENTHROX Inhaler so the exhaled vapour passes through the AC Chamber which adsorbs exhaled methoxyflurane. Multiple use without the AC Chamber creates additional risk. Elevation of liver enzymes, blood urea nitrogen and serum uric acid have been reported in exposed maternity ward staff working in delivery wards when methoxyflurane was used in the past in obstetric patients at the time of labour and delivery.

There have been reports of non-serious and transient reactions such as dizziness, headache, nausea or malaise, and reports of hypersensitivity reactions to methoxyflurane or other ingredients in healthcare professionals exposed to PENTHROX.

**Effects on laboratory tests**

No data available.

**4.5. Interaction with other medicines and other forms of interaction**

**Enzyme inducing medicines**

It is possible that enzyme inducers (such as barbiturates, alcohol, isoniazid, phenobarbital or rifampicin) which increase the rate of methoxyflurane metabolism might increase its potential toxicity and they should be avoided concomitantly with methoxyflurane.

**Adrenaline or noradrenaline**

Intravenous adrenaline or nor-adrenaline should be employed cautiously during PENTHROX administration.
**Medicines with nephrotoxic effects**

The concurrent use of tetracycline and methoxyflurane for anaesthesia has been reported to result in fatal renal toxicity. The possibility exists that PENTHROX may enhance the adverse renal effects of other medicines including certain antibiotics of known nephrotoxic potential such as gentamicin, kanamycin, colistin, polymyxin B, cephaloridine and amphotericin B.

**Narcotics**

If given concomitantly with PENTHROX, the patient should be observed closely, and the dosage for the subsequent administration of narcotics may be reduced.

Concomitant use of PENTHROX with CNS depressants e.g. opioids may produce additive depressant effects. If opioids are given concomitantly with PENTHROX, the patient should be observed closely, as is normal clinical practice with opioids.

**β-blockers**

Interaction may occur with β-blockers, with an increased risk of hypotension.

**4.6. Fertility, pregnancy and lactation**

**Pregnancy**

Use in Pregnancy (Category C). Published animal studies of some anaesthetic/analgesic/sedation medicines have reported adverse effects on brain development in early life and late pregnancy.

Published studies in pregnant and juvenile animals demonstrate that the use of anaesthetic/analgesic and sedation medicines that block NMDA receptors and/or potentiate GABA activity during the period of rapid brain growth or synaptogenesis may result in neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis when used for longer than 3 hours. These studies included anaesthetic agents from a variety of medicine classes.

**Other information**

All general anaesthetics cross the placenta and carry the potential to produce central nervous system and respiratory depression in the newborn infant. In routine practice this does not appear to be a problem; however in a compromised foetus, careful consideration should be given to this potential depression, and to the selection of anaesthetic medicines, doses and techniques.

Neonates delivered of mothers who used methoxyflurane analgesia for childbirth had a briefly raised serum uric acid, not requiring further intervention.

**Preeclampsia/ Toxaemia of pregnancy**

It is advisable not to administer PENTHROX due to the possibility of existing renal impairment.
Breast-feeding

Caution should be exercised when PENTHROX is administered to a nursing mother.

Fertility

No data available.

4.7. Effects on ability to drive and use machines

The decision as to when patients may again engage in activities requiring complete mental alertness, operate hazardous machinery or drive a motor vehicle must be individualised. Patients should be warned to take extra care as a pedestrian and not to drive a vehicle or operate a machine until the patient has completely recovered from the effects of the medicine, such as drowsiness. The treating doctor should decide when activities such as driving a vehicle or operating a machine may be resumed.

4.8. Undesirable effects

There are no data on the dose-dependency of most of the adverse medicine reactions.

Use of PENTHROX in patients with trauma and associated pain

The following Table provides treatment-emergent adverse events experienced; using System Organ Class and Preferred Term; by ≥1% of the safety population of a placebo-controlled study in patients with trauma and associated pain, of which 149 had PENTHROX.

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Methoxyflurane in Inhaler (N=149)</th>
<th>Placebo in Inhaler (N=149)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>(N=149)</td>
<td></td>
</tr>
<tr>
<td>Any Adverse Event</td>
<td>188 (88 (59.1%)</td>
<td>111 (61 (40.9%))</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>13 (12 (8.1%))</td>
<td>13 (10 (6.7%))</td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>3 (3 (2.0%))</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (2 (1.3%))</td>
<td>5 (3 (3.4%))</td>
</tr>
<tr>
<td>Toothache</td>
<td>2 (2 (1.3%))</td>
<td>2 (2 (1.3%))</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2 (2 (1.3%))</td>
<td>5 (4 (2.7%))</td>
</tr>
<tr>
<td>General Disorders And Administration Site Conditions</td>
<td>10 (9 (6.0%))</td>
<td>6 (6 (4.0%))</td>
</tr>
<tr>
<td>Influenza Like Illness</td>
<td>0 (0)</td>
<td>3 (3 (2.0%))</td>
</tr>
<tr>
<td>Feeling drunk</td>
<td>2 (2 (1.3%))</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Category</td>
<td>Methoxyflurane in Inhaler</td>
<td>Placebo in Inhaler</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>---------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Infections And Infestations</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Influenza</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Viral infection</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Injury, Poisoning And Procedural Complications</td>
<td>9</td>
<td>6 (4.0%)</td>
</tr>
<tr>
<td>Fall</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Joint sprain</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Investigations</td>
<td>8</td>
<td>5 (3.4%)</td>
</tr>
<tr>
<td>Alanine Aminotransferase Increased</td>
<td>1</td>
<td>1 (0.7%)</td>
</tr>
<tr>
<td>Aspartate Aminotransferase Increased</td>
<td>1</td>
<td>1 (0.7%)</td>
</tr>
<tr>
<td>Blood lactate dehydrogenase increased</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Musculoskeletal And Connective Tissue Disorders</td>
<td>4</td>
<td>3 (2.0%)</td>
</tr>
<tr>
<td>Back Pain</td>
<td>3</td>
<td>3 (2.0%)</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>118</td>
<td>74 (49.7%)</td>
</tr>
<tr>
<td>Amnesia</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>50</td>
<td>44 (29.5%)</td>
</tr>
<tr>
<td>Dysarthria</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Headache</td>
<td>51</td>
<td>32 (21.5%)</td>
</tr>
<tr>
<td>Migraine</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>8</td>
<td>8 (5.4%)</td>
</tr>
<tr>
<td>Reproductive System and Breast disorders</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Dysmenorrhoea</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Respiratory, Thoracic And Mediastinal Disorders</td>
<td>5</td>
<td>5 (3.4%)</td>
</tr>
<tr>
<td>Cough</td>
<td>2</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td>Oropharyngeal Pain</td>
<td>3</td>
<td>3 (2.0%)</td>
</tr>
</tbody>
</table>
In listings below, are Adverse Reactions (adverse effects that are related to the treatment) which occurred at a rate lower than in the Table above. They are listed by system organ class and frequency (common ≥1/100 to <1/10: uncommon ≥1/1,000 to <1/100; and rare ≥1/10,000 to <1/1,000).

Nervous system disorders: Uncommon: Dysgeusia, Paraesthesia
Gastrointestinal disorders: Uncommon: Oral discomfort
General disorders and administration site conditions: Uncommon: Fatigue, Feeling abnormal, Feeling of relaxation, Hangover, Hunger, Shivering
Eye disorders: Uncommon: Diplopia
Psychiatric disorders: Uncommon: Inappropriate affect

Use of PENTHROX for pain relief in patients who require it for surgical procedures

The following Table provides medicine-associated events (Adverse Reactions) experienced by ≥ 2% of the safety population of a placebo-controlled study in patients in a minor surgical procedure, of which 49 had PENTHROX for the relief of pain.
<table>
<thead>
<tr>
<th></th>
<th>Methoxyflurane in Inhaler (N=49)</th>
<th>Placebo in Inhaler (N=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>N (%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1</td>
<td>(2%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1</td>
<td>(2%)</td>
</tr>
<tr>
<td>Depression</td>
<td>1</td>
<td>(2%)</td>
</tr>
<tr>
<td>Neuropathy: sensory</td>
<td>1</td>
<td>(2%)</td>
</tr>
<tr>
<td>Somnolence / depressed level of consciousness</td>
<td>1</td>
<td>(2%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>(0%)</td>
</tr>
</tbody>
</table>

**Adverse events 48 Hours after Procedure**

<table>
<thead>
<tr>
<th></th>
<th>Methoxyflurane in Inhaler</th>
<th>Placebo in Inhaler</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>N (%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2</td>
<td>(4.1%)</td>
</tr>
<tr>
<td>Somnolence / depressed level of consciousness</td>
<td>2</td>
<td>(4.1%)</td>
</tr>
<tr>
<td>Confusion</td>
<td>1</td>
<td>(2%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>0</td>
<td>(0%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>(0%)</td>
</tr>
<tr>
<td>Musculoskeletal / soft tissue</td>
<td>1</td>
<td>(2%)</td>
</tr>
</tbody>
</table>

**Post-marketing experience**

The following additional adverse effects have also been reported in the literature and patients receiving analgesia:

**Nervous system disorders:** altered state of consciousness, nystagmus  
**Respiratory, thoracic and mediastinal disorders:** choking, hypoxia, respiratory depression  
**Hepatobiliary disorders:** hepatitis, hepatic failure, jaundice, liver injury  
**Renal and urinary disorders:** renal failure  
**Eye disorders:** vision blurred  
**Psychiatric disorders:** affect lability, agitation, confusional state, dissociation, restlessness  
**Vascular disorders:** blood pressure fluctuation  
**Investigations:** blood uric acid increased, blood urea increased, blood creatinine increased, hepatic enzymes increased

Hepatic toxicity in association with methoxyflurane is rare but has been observed with analgesic use.
The following adverse effects have been reported in association with historical use as an anaesthetic:

**Common:** retrograde amnesia, nausea, vomiting, coughing, drowsiness, sleeping, dizziness, dislike of odour, fever, polyuria, headache.
**Rare:** non-specific hepatitis, malignant hyperthermia
**Other reported events:** cardiac arrest, respiratory depression, laryngospasm, bronchospasm, hypotension, bradycardia, renal failure, increased serum urea, increased serum creatinine, increased urinary oxalate excretion, increased serum inorganic fluoride, pallor, muscle relaxation

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after Consent to Distribute of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions

https://pophealth.my.site.com/carmreportnz/s/

4.9. Overdose

**Symptoms**

In the event of overdose, anaesthetic effects may occur with signs of excessive drowsiness, (including loss of consciousness), lowering of blood pressure, respiratory depression, pallor and muscle relaxation. After PENTHROX discontinuation such overdose effects usually resolve quickly often with no other intervention required but cardiorespiratory supportive measures can be implemented if necessary.

High doses of methoxyflurane cause dose related nephrotoxicity. High output renal failure has occurred several hours or days after the administration of repeated high analgesic or anaesthetic doses of methoxyflurane.

**Treatment**

In the event of excessive urinary output following overdosage, fluid and electrolyte losses should be promptly replaced.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. **PHARMACOLOGICAL PROPERTIES**

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Other analgesics, ATC code: N02BG09

**Mechanism of action**
Methoxyflurane vapour provides analgesia when inhaled at low concentrations. After methoxyflurane administration, drowsiness may occur. During methoxyflurane administration, the cardiac rhythm is usually regular. The myocardium is only minimally sensitised to adrenaline by methoxyflurane. In light planes of anaesthesia, some decrease in blood pressure may occur. This may be accompanied by bradycardia. The hypotension noted is accompanied by reduced cardiac contractile force and reduced cardiac output.

**Clinical trials**

No data available.

5.2. *Pharmacokinetic properties*

**Absorption**

Partition coefficients at 37 °C

- A water/gas coefficient of 4.5
- A Blood/gas coefficient (mean range) of 10.20 to 14.06
- An Oil/gas coefficient of 825

The vapour concentration of methoxyflurane is limited by its vapour pressure at room temperature to a maximum of about 3.5% at 23°C.

**Distribution**

Methoxyflurane is more susceptible to metabolism than other halogenated methyl ethyl ethers and has greater propensity to diffuse into fatty tissues. Hence methoxyflurane is released slowly from this reservoir and becomes available for biotransformation for many days.

**Biotransformation**

Biotransformation of methoxyflurane occurs in man. As much as 50-70% of the absorbed dose is metabolised to free fluoride, oxalic acid, difluoromethoxyacetic acid, and dichloroacetic acid. Both the free fluoride and the oxalic acid can cause renal damage in large doses, however dose-related nephrotoxicity seen with clinical doses appears related to a combination of free fluoride and dichloroacetic acid.

**Elimination**

Approximately 20% of methoxyflurane uptake is recovered in the exhaled air, while urinary excretion of organic fluorine, fluoride and oxalic acid accounts for about 30% of the methoxyflurane uptake. Studies have shown that higher peak blood fluoride levels are obtained earlier in obese than in non-obese and in the elderly.

5.3. *Preclinical safety data*

**Embryo development**

Refer to Section 4.6.
Genotoxicity
No data available.

Carcinogenecity
No data available.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients
Butylated hydroxytoluene

6.2. Incompatibilities
Not applicable.

6.3. Shelf life
36 months.

6.4. Special precautions for storage
Store below 30°C.

6.5. Nature and contents of container
PENTHROX (methoxyflurane) is supplied in the following presentations:
- a) Pack of ten 3 mL sealed bottle with a tear off tamper seal,
- b) Combination pack with one 3 mL sealed bottle and one PENTHROX® Inhaler and Activated Carbon (AC) Chamber,
- c) Single Combination Pack containing ten 3 mL bottles and ten PENTHROX® Inhaler
- d) Double Combination Pack containing two 3 mL bottles PENTHROX® Inhaler and Activated Carbon (AC) Chamber (Pack of ten)
- e) Combination Pack containing 1.5 mL bottle, PENTHROX® Inhaler and Activated Carbon (AC) Chamber.
- f) Single Combination Pack containing ten 1.5 mL bottles and ten PENTHROX® Inhalers

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling
To reduce occupational exposure to methoxyflurane, the PENTHROX inhaler should be used with the Activated Carbon (AC) Chamber. Patients should be instructed to exhale into the PENTHROX inhaler so the exhaled vapour passes through the AC Chamber which adsorbs exhaled methoxyflurane (refer to Section 4.4). Similarly refilling must be conducted in a well-ventilated area to reduce environmental exposure to PENTHROX vapour.
Any unused medicine or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

Prescription medicine

8. SPONSOR

Douglas Pharmaceuticals Ltd
P O Box 45 027
Auckland 0651
New Zealand
Phone: (09) 835 0660

9. DATE OF FIRST APPROVAL

4 April 2002

10. DATE OF REVISION OF THE TEXT

07 November 2023

Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>Added statement that Penthrox is to only be used as an analgesic. Added statement to fill penthrox in a well-ventilated area. Added emphasis to use the lowest effective dose in children and elderly. Added statement to carefully monitor total dose. Added statement that: “Methoxyflurane-associated renal failure is generally irreversible”. Added clarity to method of administration diagrams.</td>
</tr>
<tr>
<td>4.4</td>
<td>Added statement about risk in renal disease. Added statement that “Daily use of methoxyflurane is not recommended because of nephrotoxic potential.” Added new paragraph about Respiratory depression as was requested by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA). Added additional safety statements concerning Occupational exposure.</td>
</tr>
<tr>
<td>4.8</td>
<td>Addition of respiratory depression. Reporting URL has been revised to <a href="https://pophealth.my.site.com/carmreportnz/s/">https://pophealth.my.site.com/carmreportnz/s/</a>.</td>
</tr>
<tr>
<td>4.9</td>
<td>Added more detail concerning possible symptoms that could be</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>5.2</td>
<td>Added more detail concerning distribution of methoxyflurane after use.</td>
</tr>
<tr>
<td>4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8 and 5.1</td>
<td>Minor editorial changes</td>
</tr>
<tr>
<td>6.5</td>
<td>The section has been revised to clarify all the pack presentations.</td>
</tr>
<tr>
<td>6.6</td>
<td>Addition of information to reduce occupational exposure</td>
</tr>
</tbody>
</table>